You can buy or sell Globus Medical and other stocks, options, ETFs, and crypto commission-free!
Globus Medical, Inc. operates as a medical device company that develops and commercializes healthcare solutions. The firm engages in developing products that promote healing in patients with musculoskeletal disorders. Read More It classifies products into Innovative Fusion and Disruptive Technology. It operates through the United States and International geographical segments. The company was founded by David C. Paul in March 2003 and is headquartered in Audubon, PA.
52 Week High
52 Week Low
Yahoo FinanceMay 24
Globus Medical Reveals Positive Study Results for ExcelsiusGPS
Globus Medical, Inc. GMED recently revealed the positive outcomes of a clinical study, which highlighted the efficiency of its ExcelsiusGPS Robotic navigation over traditional pedicle screw placement techniques. Results of this study reached a milestone for the musculoskeletal solutions major in the field of robotics-assisted, minimally invasive pedicle screw placement procedure. Outcomes of Study in Detail The study evaluated the technique, using which the ExcelsiusGPS advanced navigated robotic technolo...
Current Change: Globus Medical (NYSE: GMED)
Globus Medical is in the medical devices industry and trades as part of the healthcare sector. The company CEO is David M. Demski. Globus Medical Inc is a medical device company. It operates under two divisions that include innovative fusion and disruptive technology developing products for patients with musculoskeletal disorders for various treatment. Previous Intraday Trading Performance: The GMED stock showed a previous change of -1.62% with an open at 43.50 and a close of 43.25. It reached an intraday...
Globus Medical (GMED) Q1 Earnings Miss, Revenues Grow Y/Y (Revised)
Globus Medical, Inc. GMED reported first-quarter 2019 adjusted earnings per share (EPS) of 36 cents, missing both the Zacks Consensus Estimate and the year-ago figure by 12.2%. On a reported basis, the company registered earnings of 33 cents per share, translating to a 15.4% decline from the year-ago quarter. Revenue Details First-quarter 2019 worldwide sales summed $182.9 billion, up 4.9% (up 5.7% at constant exchange rate or CER) year over year. The figure, however, lagged the Zacks Consensus Estimate ...
Expected Jul 31, After Hours